Tag: commission

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.

This strategic initiative with the Ministry of Economy of Ukraine aims to fast-track digital infrastructure development, unlock scalable AI adoption, and underpin sustainable long-term economic growth.

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4

London, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) --

BulkQuant, a fully managed AI trading robot platform, is expanding its automated trading ecosystem to help retail investors explore structured trading strategies across cryptocurrency, forex, and stock market environments.

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.